Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Accel. buyback
Quarterly results
Auditor change
AbbVie Inc. (ABBV) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/04/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/27/2023 8-K Quarterly results
Docs: "AbbVie Reports Second-Quarter 2023 Financial Results"
07/25/2023 144 Form 144 - Report of proposed sale of securities:
07/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/28/2023 11-K Form 11-K - Annual report of employee stock purchase, savings and similar plans:
06/09/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
05/31/2023 SD Form SD - Specialized disclosure report:
05/10/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/05/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
04/27/2023 8-K Quarterly results
04/25/2023 144 Form 144 - Report of proposed sale of securities:
04/20/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/05/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
03/28/2023 8-K Quarterly results
03/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/28/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
03/27/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
03/21/2023 ARS Form ARS - Annual Report to Security Holders:
03/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/20/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/06/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 9% stake in AbbVie Inc.
02/09/2023 8-K Quarterly results
01/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "J.P. Morgan Healthcare Conference | January 10, 2023 2 Forward - Looking Statements and Non - GAAP Financial Information Some statements in this presentation are, or may be considered, forward - looking statements for purposes of the Private Securitie s Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or cond iti onal verbs, generally identify forward - looking statements. AbbVie cautions that these forward - looking statements are subject to risks and un certainties that may cause actual results to differ materially from those expressed or implied in the forward - looking statements. Such risks and uncertainties include, but are not limited to, challenges..."
01/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
11/29/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy